Stock screenerAll disclosures →
EDGAR →
NVAX
Conviction 49HealthcareScan · Thu, Jun 25, 2026NVAX$8.55-3.93%
ResistanceSupportVol 14Vol MA14 4.73M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price8.55
Change-3.93%
Gap+0.56%
Rel volume1.69×
Avg volume4.93M
Avg $ vol46.54M
SMA 209.41
SMA 509.09
SMA 2008.49
Price vs 50-5.97%
Price vs 200+0.70%
MA stackmixed
50/200 cross—
Supertrenddown · 10.55
RSI (14)41
MACD hist-0.09
MACD cross—
Stoch %K / %D15 / 23
ADX (14)19
+DI / −DI22 / 21
RSI divergence—
MACD divergence—
ATR %+7.49%
ADR %6.66%
52w high11.19
52w low6.22
From 52w high-23.59%
Above 52w low+37.46%
New 52w highNo
SqueezeOff
Bollinger width30.33%
%B0.20
Donchian pos9.59%
Donchian high11.19
Donchian low8.27
AVWAP (52w high)9.47
vs AVWAP high-9.71%
AVWAP (52w low)8.90
vs AVWAP low-3.92%
OBV trendDown
Chaikin MF (20)-0.32
Today vs 20d1.69×
Avg vol (14d)4.73M
Avg vol (20d)4.93M
Avg $ vol (20d)46.54M
Market cap1.41B
RS 3m (vs SPY)-16.14%
RS 6m (vs SPY)+25.90%
RS line new highNo
Trend template6/8
Technical rank45.6
1 week-10.00%
1 month-18.26%
3 months-8.46%
6 months+24.09%
1 year+31.74%
YTD+19.92%
P/E3.19
P/B-9.71
P/S1.25
P/FCF—
EPS2.58
Div yield—
ROE-304.16%
ROA42.21%
Debt/Eq-2.01
Current2.48
EV/EBITDA3.06
Gross margin—
Net margin39.19%
Rev growth64.69%
EPS growth334.83%
Price target12.83
Target upside50.06%
Analyst ratingBuy
Institutional81.39%
Ent. value1.47B
Revenue139.51M
Net income-9.49M
Gross profit—
Free cash flow—
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out164.44M
Employees749
ListedTue, Dec 5, 1995
Free float154.66M
Float %94.9%
Short interest45.97M
Days to cover7.8d
Short volume45.8%
Squeeze score79 / 100
Next earningsWed, Aug 5, 2026 (41d)
EPS forecast−$0.36 · 4 est
Last EPS vs est−$0.06 vs −$0.25
Last surprise+76.0% beat
Setup gradeC
Conviction49 / 100
Pattern quality—
Tech rank45.6 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance11.18
Support8.08
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in NVAX
No recent disclosed trades by Congress in NVAX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in NVAX · 3 buys · 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Newton Charles W. Director · Common Stock · 2026-04-25 | Exercise | 9.52K | $0 | 2026-04-25 | 2026-04-28 |
Newton Charles W. Director · Restricted Stock Units · 2026-04-25 | Exercise | 9.52K | $0 | 2026-04-25 | 2026-04-28 |
Walker Robert Edward EVP, R&D · Restricted Stock Units · 2026-04-14 | Grant | 66K | $0 | 2026-04-14 | 2026-04-16 |
Walker Robert Edward EVP, R&D · Stock Option (Right to Buy) · 2026-04-14 | Grant | 99.5K | $0 | 2026-04-14 | 2026-04-16 |
SEC filings
EDGAR filings in NVAX · 1 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.